Gross Proceeds of Offering Total 115.0 Million
NEWARK, Calif.--(BUSINESS WIRE)--Jan. 22, 2019--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions (“Revance” or the “Company”), today announced
the closing of an underwritten public offering of 6,764,705 shares of
its common stock at a price to the public of $17.00 per share, including
the exercise in full by the underwriters of their option to purchase
882,352 additional shares of common stock. The gross proceeds to the
Company from the offering, before deducting the underwriters’ discounts
and other estimated offering expense payable by the Company, were
approximately $115.0 million.
Goldman Sachs & Co. LLC, Cowen and Piper Jaffray acted as book-running
managers and Guggenheim Securities acted as lead manager.
The securities described above were offered by Revance pursuant to an
automatic shelf registration statement previously filed with the
Securities and Exchange Commission on December 5, 2017. The offering was
made only by means of a prospectus supplement. When available, copies of
the prospectus supplement and accompanying prospectus relating to the
proposed public offering may be obtained by contacting Goldman Sachs &
Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282,
telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com;
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by
emailing PostSaleManualRequests@broadridge.com;
or Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by
email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a clinical-stage biotechnology company focused on the
development, manufacturing, and commercialization of novel
neuromodulators for multiple aesthetic and therapeutic indications.
Revance is leveraging its proprietary portfolio of botulinum toxin type
A compounds, formulated with its patented and proprietary peptide
excipient technology, to address unmet needs in large and growing
neuromodulator markets.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005823/en/
Source: Revance Therapeutics, Inc.
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
John Grimaldi, 212-213-0006
jgrimaldi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com